Quick Answer
KALA BIO, Inc. reported Diluted EPS of $10.15 per share (loss) for fiscal year 2024.
KALA BIO, Inc. Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2024 | -$10.15 | +41.5% |
| 2023 | -$17.35 | +41.1% |
| 2022 | -$29.48 | +72.8% |
| 2021 | -$108.32 | -5343.2% |
| 2020 | -$1.99 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$1.07 | +44.6% | +37.4% |
| June 30, 2025 | -$1.71 | +45.9% | -21.3% |
| March 31, 2025 | -$1.41 | +66.4% | +26.9% |
| September 30, 2024 | -$1.93 | +43.4% | +38.9% |
| June 30, 2024 | -$3.16 | +27.5% | +24.8% |
| March 31, 2024 | -$4.20 | +39.9% | -23.2% |
| September 30, 2023 | -$3.41 | -117.7% | +21.8% |
| June 30, 2023 | -$4.36 | +77.0% | +37.6% |
- KALA BIO, Inc. showed an increase of +41.5% in Diluted EPS compared to the prior fiscal year.
- Over the 2020–2024 period, KALA BIO, Inc.’s diluted eps has declined by 410.1% (from $1.99 per share (loss) to $10.15 per share (loss)).
- The most recent figure is from KALA BIO, Inc.’s fiscal year 2024 report (Form 10-K), filed with the SEC on March 31, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: